Austrian Biotech Startup LifeTaq Collapses After Bold Bid to End Animal Testing

LifeTaq, an Austrian biotech startup focused on replacing animal testing in drug research, has filed for insolvency. The company had developed a fully automated machine for 3D tissue models, aiming to provide an ethical and scientifically advanced alternative. Despite ambitious projections and public backing, financial struggles led to its collapse.

LifeTaq was founded with a clear mission: to eliminate animal testing in pharmaceutical research. Its technology centred on a high-tech culture machine capable of growing 3D tissue models, offering a more reliable and cruelty-free method for drug development.

The company secured €3.5 million in funding from the Austrian Research Promotion Agency (FFG). It also launched a crowdfunding campaign, raising over €300,000—even while operating with a negative balance sheet. Confidence in the project was high, with forecasts suggesting profitability from just four machine sales and potential earnings of €4 million by 2027.

However, financial difficulties persisted. Despite public support and early optimism, LifeTaq's situation worsened over time. The company ultimately filed for bankruptcy, leaving the future of its technology and remaining assets unclear. Competitors may now step in to acquire its innovations.

No broader trend in Austrian biotech insolvencies has been reported, and no other high-profile cases have emerged since 2020.

LifeTaq's bankruptcy marks the end of a venture that once promised to revolutionise drug testing. The company's automated 3D tissue technology had drawn significant investment and public interest. What happens next to its assets—and whether its work will continue under new ownership—remains to be seen.